Skip to main content
  • Zirabev, Mvasi May Not Be Used to Treat Eye Disease, CMS Says

    CMS has told Medicare Advantage plans that the two biosimilars, which are not clinically proven to treat eye disease and are potentially dangerous to ophthalmology patients, may not be used as substitutes for Avastin or be required in their step therapy programs.